战斗环境下头部创伤后给予氨甲环酸:能否改善神经功能结局?
该回顾性研究纳入2008至2015年北约驻伊拉克和阿富汗医院收治的4476例18岁以上创伤患者,其中174例(3.9%)接受了氨甲环酸。接受氨甲环酸者损伤严重度评分更高、穿透伤更多、初始格拉斯哥昏迷评分更低、严重颅脑损伤比例更高且输血需求更大。经倾向性匹配后的92例患者中,接受氨甲环酸者死亡率显著更低(0% vs 10.1%,p=0.02),出院格拉斯哥昏迷评分改善至14至15分的比例显著更高(100% vs 87%,p=0.01),两组血栓栓塞事件数无显著差异。作者结论认为氨甲环酸给药与死亡率降低和神经功能结局改善独立相关,且未增加血栓栓塞事件,但需进一步研究其机制和效应。
要点
- 倾向性匹配队列中,接受氨甲环酸者死亡率0% vs 未接受者10.1%(p=0.02),出院格拉斯哥昏迷评分改善至14至15分者100% vs 87%(p=0.01)。
- 接受氨甲环酸者损伤更重:损伤严重度评分更高、穿透伤更多、初始格拉斯哥昏迷评分更低、严重颅脑损伤(简明损伤定级>3)比例更高、输血需求更大。
- 两组记录的血栓栓塞事件数无显著差异。
- 该研究为回顾性研究,证据等级为治疗性IV级,作者认为需进一步研究氨甲环酸对颅脑损伤和神经功能结局的可能机制与效应。
适用人群与场景
- 2008年至2015年北约驻伊拉克和阿富汗医院收治的18岁以上成人创伤患者;无头部简明损伤定级记录者被排除。
研究设计与关键结果
- 回顾性研究纳入4476例18岁以上创伤患者,265例(5.9%)在最初24小时内需大量输血,174例(3.9%)接受氨甲环酸。
- 接受氨甲环酸者损伤严重度评分显著更高、穿透伤更多、初始格拉斯哥昏迷评分更低、严重颅脑损伤(简明损伤定级>3)发生率更高、输血需求更高。
- 倾向性匹配队列共92例;接受氨甲环酸者死亡率显著更低(0% vs 10.1%,p=0.02),出院格拉斯哥昏迷评分改善至14至15分的比例显著更高(100% vs 87%,p=0.01),且与入院格拉斯哥昏迷评分无关。
- 两组记录的血栓栓塞事件数无显著差异。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:治疗性IV级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在成人战斗创伤患者中给予氨甲环酸与死亡率降低和神经功能结局改善独立相关,且未增加血栓栓塞事件。
- 作者认为,需进一步研究氨甲环酸对颅脑损伤和神经功能结局的可能机制与效应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) has been shown to decrease mortality and blood product requirements in severely injured patients. Tranexamic acid has also been hypothesized to prevent secondary brain injury in patients with traumatic brain injury. While prior studies have demonstrated improved neurologic outcomes associated with TXA administration in severely injured pediatric patients, no such studies have been performed in adults.
METHODS: A retrospective review of all adult trauma admissions to North Atlantic Treaty Organization hospitals in Iraq and Afghanistan between 2008 and 2015. Univariate and multivariate analysis was used to identify factors associated with TXA administration. Patients without a documented head Abbreviated Injury Scale (AIS) were excluded. Patients were propensity matched based on demographics, mechanism of injury, Injury Severity Score (AIS/ISS), presenting Glasgow Coma Scale (GCS) score, initial vitals/laboratory values, and initial transfusion requirement. Primary outcomes were in-hospital mortality and neurologic outcomes measured by discharge GCS scores. Secondary outcomes were respiratory failure and rates of thromboembolic events.
RESULTS: Four thousand four hundred seventy-six injured patients 18 years or older were evaluated. Two hundred sixty-five (5.9%) of these patients required a massive transfusion in the first 24 hours, and 174 (3.9%) received TXA. The TXA patients had significantly higher ISS, more penetrating injuries, lower presenting GCS, higher incidence of severe head injury (AIS > 3), and higher transfusion requirements. Ninety-two patients were included in the propensity matched cohort. Of these, patients who received TXA had significantly lower mortality rate (0% vs. 10.1%, p = 0.02) and improvement of GCS score to 14 to 15, irrespective of admission GCS compared with patients who did not receive TXA (100% vs. 87%, p = 0.01). There were no significant differences in number of thromboembolic events recorded between the two groups.
CONCLUSION: The TXA administration in adult combat trauma patients was independently associated with decreased mortality and improved neurologic outcomes, with no increase in thromboembolic events. Further study of the possible mechanisms and effect of TXA on brain injury and neurologic outcomes is warranted.
LEVEL OF EVIDENCE: Therapeutic, level IV.
参考来源
- Morte D, Lammers D, Bingham J, et al. Tranexamic acid administration following head trauma in a combat setting: Does tranexamic acid result in improved neurologic outcomes? J Trauma Acute Care Surg. 2019. PMID: 30908452. doi:10.1097/TA.0000000000002269
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。